Tagged with Interview

Pharma Samsung is focused on the total digital transformation of medical services. It offers solutions in mobile health, hospital digitalization, and integrated medical and healthcare devices. The head of the healthcare and medical equipment division in Italy Dario Guido discusses how Samsung plans to catalyze a ‘digital transformation’ in Italian healthcare…

Pharma The country manager of Berlin-Chemie / A. Menarini Hungary, Dr. Peter Olah, explains the impact of a more targeted sales force in driving the company in the last three years, while highlighting his ambitions to push the affiliate into more specialty care. He also describes the most salient challenges currently…

Pharma Agnès Ducrot and Miklos Maróthy of CCI France Hongrie discuss their advocacy efforts in Hungary and the history of French investment in the country. They also discuss the challenges and opportunities facing companies currently operating in the country. Can you give our readers an overview of the Chamber’s activities here in…

Pharma Ahead of the imminent acquisition of Baxalta by Shire, country managing director Italy Fabio Andreola shares his perspective on the rare-disease environment in Italy and how Baxalta will contribute to making the new combined company the undisputed leader in the treatment of rare diseases. How would you assess the Italian…

Pharma Sebastien Aguettant, president of the French Association of Pharmaceutical Contract Manufacturers (SPIS) and president of leading French CMO Delpharm, discusses the evolutions and growing significance of contract manufacturing, how CMO pharma manufacturing has only just begun, and how Delpharm with its ten sites in France is a reliable partner of…

Pharma The executive director of the Česká asociace farmaceutických firem, the Czech Republic’s generic pharmaceutical association, elaborates on the code of ethics recently implemented and followed by all its members, which exceed the standards set in current legislation. Furthermore, he explains the implications for the industry of the ongoing EU-level discussions…

Pharma The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much greater emphasis on value demonstration and patient-level data. You have been General Manager at IMS Health for 8 years. During…

Pharma Maurizio Marchesini, CEO of Marchesini Group, discusses the challenges of competing in a very dynamic packaging machinery industry, where their business is differentiated through flexibility and integral service offerings. Further, he talks about how internationalization into developing regions will drive the growth of the group. To begin, could you please…

Pharma Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and MolMed. Can you please give our readers a brief rundown of the history of MolMed since its foundation in 1996?…

Pharma Paolo Marcucci, President and CEO of Kedrion Biopharma, talks about the factors behind the company’s incredible growth and its commitment to doubling exports to the US. Furthermore, he talks about the challenges and opportunities the company encountered while supporting the national health system to become self-sufficient in plasma-collection and fractionation.…

Pharma Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative medicines to patients with rare diseases and other specialty conditions. Could you please start by describing the company’s engagement with…

Pharma Genfit’s Jean-François Mouney speaks about responding to high unmet medical needs in inflammatory and metabolic related diseases. With the increase in obesity related diseases, Mouney discusses their lead pipeline product: Elafibranor, the new orphan blockbuster drug aimed at curing NASH; nonalcoholic steatohepatitis and other related diseases.   As an entrepreneur…